NL-OMON44216已完成不适用
A Randomized, Placebo-Controlled, Double-Blind, Parallel Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of LTI-291 in Patients with Parkinson*s Disease and a GBA1 Mutation - Phase 1b study for LTI-291
ysosomal Therapeutics Incorperated0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Signed informed consent prior to any study-mandated procedure.
- •2. Minimum age of 18 years.
- •3. Clinical diagnosis of Parkinson*s Disease at least 6 months prior to screening, confirmed by a neurologist.
- •4. A score of 1-4 on Hoehn & Yahr Scale.
- •5. Mutation(s) in glucocerebrosidase GBA1 gene.
- •6. 6. Mini Mental State Exam score >/<= 18 and assessed by the investigator or qualified designee as able to provide informed consent.
- •7. Body mass index (BMI) between 18 and 35 kg/m2, inclusive, and with a minimum weight of 45 kg at screening.
- •8. All females must be at least 2 years post-menopausal or surgically sterile or practice higly effective contraception until at least 90 days after their last dose of study treatment.
- •9. All males must practice effective contraception and abstain from sperm donation during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
- •10. Has the ability to communicate well with the investigator in the Dutch language and willing to comply with the study restrictions.
排除标准
- •1. Any active or chronic disease or condition other than PD that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following medical history review, physical examination, vital signs (supine systolic and diastolic blood pressure, pulse rate, body temperature), 12-lead electrocardiogram (ECG), and clinical laboratory parameters (hematology, blood chemistry, and urinalysis)). Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance.
- •2. History of recent major surgery (within 60 days of screening) that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
- •3. Atypical or secondary parkinsonism by medical history or in the opinion of the investigator. Atypical parkinsonism includes, but not limited to a diagnoses of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy. Secondary parkinsonism includes drug-induced, post-infectious, post-traumatic and vascular parkinsonisms.
- •4. Patients that experience Freezing Of Gait (FOG) in the on-state of L-dopa treatment (paradoxical response), which might interfere with the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
- •5. Current (within last 30 days prior to start of clinical phase) use of a strong CYP3A4 modulator. Reference Appendix B for a list of prohibited CYP3A4 modulators.
- •6. Current use of any drug known to significantly inhibit blood coagulation in the opinion of the investigator.
- •7. Vaccination within 7 days prior to start of dosing.
- •8. Any contra-indication for undergoing a lumbar puncture procedure (e.g. anatomical variations or local skin infection).
- •9. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •10. Participation in an investigational drug or therapeutic device study within 3 months prior to first dosing, or within 6 months for a biologic investigational product.
- •11. Recent history (last 6 months) of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units of alcohol per week, drug abuse, or regular recreational user of sedatives, hypnotics, tranquillizers, or any other addictive agent.
- •12. Positive test for drugs of abuse at screening or pre-dose.
- •13. Women currently pregnant or breastfeeding.
- •14. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening or intention to donate blood or blood products during the study.
- •15. Any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prevention of Episodic Cluster HeadacheEUCTR2012-003729-62-GBCENTER LABORATORIES, INC30
进行中（未招募）
不适用
A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects with Partly Controlled Atopic AsthmaAsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-002816-97-GBPulmagen Therapeutics LLP36
进行中（未招募）
2 期
Test of the effect of 1-Kestose on the intestinal environment of Pregnant Women.JPRN-jRCTs031210087Ide Yoshihiro70
进行中（未招募）
1 期
Investigation of CRD007 in asthma patientsAsthmaEUCTR2015-002656-26-BGRSPR Pharma AB160
进行中（未招募）
1 期
Investigation of CRD007 in asthma patientsMedDRA version: 18.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2015-002656-26-DKRSPR Pharma AB160